CY1118664T1 - Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου - Google Patents

Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Info

Publication number
CY1118664T1
CY1118664T1 CY20171100260T CY171100260T CY1118664T1 CY 1118664 T1 CY1118664 T1 CY 1118664T1 CY 20171100260 T CY20171100260 T CY 20171100260T CY 171100260 T CY171100260 T CY 171100260T CY 1118664 T1 CY1118664 T1 CY 1118664T1
Authority
CY
Cyprus
Prior art keywords
toxin
difficile
toy
proteins
tab
Prior art date
Application number
CY20171100260T
Other languages
English (en)
Inventor
Larry Ellingsworth
David Flyer
Jing-Hui Tian
Steven Fuhrmann
Stefanie Kluepfel-Stahl
Gregory Glenn
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118664(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CY1118664T1 publication Critical patent/CY1118664T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 που περιέχουν τις περιοχές δέσμευσης υποδοχέα τοξίνης Α και τοξίνης Β του C. difficile όπως παρατίθενται στις αλληλουχίες αμινοξέων της SEQ ID NO: 2 και SEQ ID NO: 4. Τα απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 μπορούν να χρησιμοποιηθούν σε εξουδετέρωση των τοξικών επενεργειών τοξίνης Α και/ή τοξίνης Β του C. difficile.
CY20171100260T 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου CY1118664T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (1)

Publication Number Publication Date
CY1118664T1 true CY1118664T1 (el) 2017-07-12

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100260T CY1118664T1 (el) 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Country Status (22)

Country Link
US (6) US9598472B2 (el)
EP (3) EP2753352B2 (el)
JP (1) JP6121421B2 (el)
KR (1) KR101907434B1 (el)
CN (1) CN103957931B (el)
AU (1) AU2011298306B2 (el)
BR (1) BR112014004896B1 (el)
CA (1) CA2873272C (el)
CY (1) CY1118664T1 (el)
DK (1) DK2753352T4 (el)
ES (2) ES2631032T5 (el)
HK (1) HK1200357A1 (el)
HR (1) HRP20170193T4 (el)
HU (1) HUE033342T2 (el)
LT (1) LT2753352T (el)
MX (1) MX350126B (el)
PL (1) PL2753352T5 (el)
PT (1) PT2753352T (el)
RS (1) RS55707B2 (el)
SI (1) SI2753352T2 (el)
WO (1) WO2012028741A1 (el)
ZA (1) ZA201400610B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502998A3 (en) * 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
EP4365196A3 (en) 2011-04-22 2024-08-07 Wyeth LLC Compositions relating to a mutant clostridium difficile toxin and methods thereof
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
PL3138916T3 (pl) * 2011-05-27 2019-11-29 Glaxosmithkline Biologicals Sa Kompozycja immunogenna
JP6084631B2 (ja) 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
DK2928489T3 (en) 2012-12-05 2019-04-23 Glaxosmithkline Biologicals Sa IMMUNOGENE COMPOSITION
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
US10533036B2 (en) * 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
US10913786B2 (en) * 2016-03-21 2021-02-09 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
CA3059817A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
US20220144924A1 (en) * 2019-02-25 2022-05-12 Previpharma Consulting Gmbh Epitopes of clostridium difficile toxins a and b and uses thereof
WO2021205017A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
DE69610106D1 (de) 1995-07-07 2000-10-05 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
US6365573B1 (en) 1996-10-04 2002-04-02 Neuronz Ltd. Regulation of neural enzymes
JP2001512329A (ja) 1996-12-31 2001-08-21 アルテア テクノロジーズ，インコーポレイテッド 生物活性薬剤送達のための組織微穿孔
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
SK287689B6 (sk) 2000-06-08 2011-06-06 Intercell Ag Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1390495B1 (en) 2001-05-21 2007-07-04 Intercell AG Immunostimulatory oligodeoxynucleic molecules
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
WO2006024024A2 (en) 2004-08-23 2006-03-02 Teva Pharmaceutical Industries Ltd. Solid and crystalline ibandronate sodium and processes for preparation thereof
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CA2693958A1 (en) * 2007-06-14 2008-12-18 Emergent Biosolutions, Inc. Chemically modified peptides with improved immunogenicity
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8986697B2 (en) * 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
EP4365196A3 (en) * 2011-04-22 2024-08-07 Wyeth LLC Compositions relating to a mutant clostridium difficile toxin and methods thereof
PL3138916T3 (pl) 2011-05-27 2019-11-29 Glaxosmithkline Biologicals Sa Kompozycja immunogenna
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
DK2928489T3 (en) 2012-12-05 2019-04-23 Glaxosmithkline Biologicals Sa IMMUNOGENE COMPOSITION
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
SI2753352T2 (sl) 2022-10-28
DK2753352T5 (da) 2017-05-01
AU2011298306B2 (en) 2017-10-19
CN103957931B (zh) 2017-10-24
US20230173052A1 (en) 2023-06-08
BR112014004896A2 (pt) 2021-01-26
DK2753352T4 (da) 2022-09-12
ZA201400610B (en) 2015-09-30
JP6121421B2 (ja) 2017-04-26
US20210121554A1 (en) 2021-04-29
EP2753352B2 (en) 2022-08-10
AU2011298306A1 (en) 2014-02-20
HRP20170193T1 (hr) 2017-06-02
RS55707B1 (sr) 2017-07-31
US20210393761A1 (en) 2021-12-23
US11478540B2 (en) 2022-10-25
HUE033342T2 (en) 2017-11-28
CN103957931A (zh) 2014-07-30
KR101907434B1 (ko) 2018-10-12
EP2753352A1 (en) 2014-07-16
ES2867375T3 (es) 2021-10-20
PT2753352T (pt) 2017-03-08
US9598472B2 (en) 2017-03-21
MX350126B (es) 2017-08-28
RS55707B2 (sr) 2022-10-31
BR112014004896B1 (pt) 2023-02-14
ES2631032T3 (es) 2017-08-25
KR20140057315A (ko) 2014-05-12
US20190290747A1 (en) 2019-09-26
US10821166B2 (en) 2020-11-03
CA2873272A1 (en) 2012-03-08
PL2753352T3 (pl) 2017-07-31
EP3167899A1 (en) 2017-05-17
US11357844B2 (en) 2022-06-14
US20170239340A1 (en) 2017-08-24
EP3167899B1 (en) 2021-03-24
US10357557B2 (en) 2019-07-23
EP2753352B1 (en) 2017-01-25
EP3895728A1 (en) 2021-10-20
ES2631032T5 (es) 2022-10-26
HRP20170193T4 (hr) 2022-09-02
MX2014002595A (es) 2014-10-13
US20150056238A1 (en) 2015-02-26
PL2753352T5 (pl) 2022-10-17
CA2873272C (en) 2020-10-27
WO2012028741A1 (en) 2012-03-08
JP2014525249A (ja) 2014-09-29
SI2753352T1 (sl) 2017-06-30
LT2753352T (lt) 2017-05-25
HK1200357A1 (en) 2015-08-07
DK2753352T3 (da) 2017-03-06

Similar Documents

Publication Publication Date Title
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
MX360741B (es) Constructos de polipéptidos y sus usos.
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
NZ628446A (en) Fibronectin based scaffold domain proteins that bind to myostatin
IN2014KN01713A (el)
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
IN2014KN01714A (el)
IN2014KN01716A (el)
NZ600732A (en) Oxyntomodulin peptide analogue
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
NZ703560A (en) Method for activating helper t cell
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
EP4374913A3 (en) Novel human serum albumin mutant
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
EP4269562A3 (en) Antigen binding molecules and methods of use thereof